Colistin is considered a last resort for the treatment of infections caused by carbapenemase-producing members of the family Enterobacteriaceae. Recently, a transferable plasmid conferring resistance to colistin was discovered in Escherichia coli and Klebsiella pneumoniae from China ([1][1]) and was
No takes yet. Share an insight, caveat, or question.
Elnahriry et al. (2016) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: